TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06918808: DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Sponsor: Direct Biologics, LLC · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$931,500

Rescue Site Savings

+$621,000

Unlock Full NCT06918808 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06918808 Rescue Dossier →